Table 5. Clinical, laboratory,... | American Society of Hematology

Table 5.

Clinical, laboratory, treatment, and outcome features of selected children who experienced relapse

Patient n	Age, y	Sex	Race	WBC, ×10⁹/L	Genotype	Relapse site	HD-MTX doses received, %	L-asparaginase doses received, %	Duration of first CR, mo	Outcome after salvage therapy
1	2.7	Male	White	8.6	ETV6-RUNXT1	Bone marrow	100	80	37	Died, infectious complications
27	3.9	Female	Mixed	4.1	ETV6-RUNXT1	Lymph nodes and kidneys	60	90	96	Alive, second CR, 28 mo
85	6.3	Male	Mixed	18.0	DNA index 1	Bone marrow and testicles	100	100	39	Alive, second CR, 12 mo
324	3.9	Male	White	6.8	DNA index 1	Bone marrow	100	80	27	Died, infectious complications
349	3.7	Male	Mixed	6.7	DNA index 1	Bone marrow	100	100	28	Died, infections complications
363	2.6	Male	Mixed	14.1	DNA index 1.16	Bone marrow and CNS	100	80	21	Alive, second CR, 12 mo

Patient n	Age, y	Sex	Race	WBC, ×10⁹/L	Genotype	Relapse site	HD-MTX doses received, %	L-asparaginase doses received, %	Duration of first CR, mo	Outcome after salvage therapy
1	2.7	Male	White	8.6	ETV6-RUNXT1	Bone marrow	100	80	37	Died, infectious complications
27	3.9	Female	Mixed	4.1	ETV6-RUNXT1	Lymph nodes and kidneys	60	90	96	Alive, second CR, 28 mo
85	6.3	Male	Mixed	18.0	DNA index 1	Bone marrow and testicles	100	100	39	Alive, second CR, 12 mo
324	3.9	Male	White	6.8	DNA index 1	Bone marrow	100	80	27	Died, infectious complications
349	3.7	Male	Mixed	6.7	DNA index 1	Bone marrow	100	100	28	Died, infections complications
363	2.6	Male	Mixed	14.1	DNA index 1.16	Bone marrow and CNS	100	80	21	Alive, second CR, 12 mo

CR, complete remission.